Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 105, Issue 7, Pages 1490-1502Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2010.2
Keywords
-
Categories
Funding
- National Institutes of Health (NCI) [RO3CA 135991-01]
- American College of Gastroenterology
- Veterans Affairs Medical Center, Kansas City
- Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic
Ask authors/readers for more resources
Barrett's esophagus (BE) is the strongest risk factor for esophageal adenocarcinoma (EAC), a malignancy with persistently poor long-term outcomes. EAC is thought to develop through progression of metaplasia to dysplasia to invasive carcinoma. Identification of factors predicting progression to EAC would help in focusing surveillance, chemoprevention, or ablation for those deemed to be at highest risk of progression. We performed a comprehensive review of the literature and summarized current evidence on risk factors for progression in subjects with known BE. Clinical and demographic factors (age, male gender, length of BE segment) are associated with modestly increased odds of progression to EAC in some studies. Biomarkers such as aneuploidy and p53 loss of heterozygosity have been associated with increased risk of progression to high-grade dysplasia and/or EAC in single-center prospective cohort studies. Promising newer techniques and markers have been recently reported with the potential to help risk stratify BE subjects. Development of a comprehensive BE risk progression score comprised of both clinical and biomarker variables should be the ultimate goal and can be achieved by multicenter prospective collaborative efforts. Although it would be challenging, creation of such a score has the potential to improve outcomes and make the management of patients with BE more cost-effective.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available